Engineered Immunologic Niche Monitors Checkpoint Blockade Response and Probes Mechanisms of Resistance
{{output}}
Antibodies to programmed cell death protein1 (anti-PD-1) have become a promising immunotherapy for triple negative breast cancer (TNBC), blocking PD-L1 signaling from pro-tumor cells through T cell PD-1 receptor binding. Nevertheless, only 10-20% of PD-L1+ met... ...
